Tm Bioscience will incorporate these markers into a diagnostic for use by critical-care physicians. The company said it expects to launch the test in the second half of 2007.
Tm said the test "could generate" more than $100 million in the first three years on the market.
Terms of the deal call for Tm Bioscience to provide Sirius an upfront payment of $4 million in two equal installments in the second and third quarters of this year. Sirius will repay this cash from earnings generated on the sale of the test. Tm and Sirius will share the remaining earnings equally over the term of the agreement.
The deal call covers a series of "possible mutations" that can occur in the genes associated with two proteins, protein C and arginine vasopressin.